Sars-Cov2 Pluslife is the innovative kit, which with RHAM molecular method, provides ease of use, sensitivity and specificity unique in the diagnostic market.
With the emergence of numerous new variants of the novel coronavirus, it has become increasingly crucial to have accurate diagnostics capable of detecting multiple strains of the coronavirus. Pluslife Biotech has accepted the challenge with its state-of-the-art SARS-CoV2 test card that has the ability to detect all common variants in 7 to 35 minutes, revolutionizing the field of SARS-CoV2 diagnostics.
The company reanalyzed the results of the alignment of detection target regions for the SARS-CoV2 Pluslife test and for SARS-CoV2 / Influenza A / Influenza B. The results confirm that the tests can accurately detect the novel coronavirus and its reported major variants, including Alpha, Beta, Gamma, Delta and Omicron, as well as all those labeled as "Variants of Interest" (VOCs) by the World Health Organization (WHO). Importantly, they also do not produce false-negative results or find off-target problems, as shown in several comparative studies.
In the world of medical diagnostics, the molecular POCT (Point-of-Care Testing) test developed by Pluslife marks a major breakthrough. This innovative diagnostic tool boasts sensitivity, specificity and accuracy that are at the upper levels, comparable to those of renowned qPCR tests, now considered the gold standard in pathogen detection.
One of the most impressive aspects of Pluslife's POCT test is its ability to identify viruses with an extremely low "Limit of Detection" (LoD), set at only 200 copies/mL. This feature not only outperforms many qPCR tests but also ensures early detection, significantly increasing the chances of timely and effective treatment.
Imagine, for example, the use of this technology during a covid or influenza outbreak but also of other pathogens that are more difficult to identify. The availability of such a sensitive and rapid test could literally transform the approach to epidemic management, enabling immediate interventions and potentially reducing the number of severe cases.